ArticleGland surgery2025
Efficacy of postoperative thyroid-stimulating hormone inhibition therapy in differentiated thyroid cancer in China: a systematic literature review and meta-analysis.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid-stimulating hormone (TSH) suppression therapy after surgery is recommended for patients with differentiated thyroid cancer (DTC) at risk of recurrence; however, evidence, including all stages of the disease, is inconclusive. A meta-analysis was conducted to assess the efficacy of postoperative treatment with or without TSH inhibition in Chinese patients who had undergone surgery for DTC. Methods: PubMed (MEDLINE), Embase, and two Chinese databases (Wanfang and China National Knowledge Infrastructure) were searched for relevant studies published from inception to 1 April 2023. Study characteristics, patient characteristics, and recurrence or metastasis data were extracted. Data from 20 prospective studies were pooled for overall effect and for effects by tumor subtype using a random-effects model. Results: Postoperative TSH suppression therapy significantly reduced recurrence risk Conclusions: This meta-analysis showed that TSH suppression therapy was effective in reducing the risk of recurrence and metastasis
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.